Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on ...

A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

CNBC’s Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report.

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

J&J's diversified business, robust pipeline, and strong free cash flow provide stability, despite legal challenges. Read more ...